Gossamer isn’t really that much of hardcore gambling. They got a promising candidate with Seralutinib for treating pulmonary hypertension. If their phase III (Prosera) delivers, which isn’t that unlikely, they got a market leader in 30 Billion dollar market.
•
33
•
6Mon
@ECB_Hater awesome, thanks for that info
•
11
•